ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Case Report
Revised

Case Report: III° atrioventricular block due to fulminant myocarditis managed with non-invasive transcutaneous pacing

[version 2; peer review: 2 approved]
* Equal contributors
PUBLISHED 23 Mar 2018
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

Fulminant myocarditis is a life-threatening clinical condition. It is the inflammation of myocardium leading to acute heart failure, cardiogenic shock and cardiac arrhythmias. Incidence of fulminant myocarditis is low and mortality is high. Most grievous complications of fulminant myocarditis is mainly cardiac arrhythmias; if there is delay on active management of the patient, it may be fatal. Here, we describe a case of III° atrioventricular block due to fulminant myocarditis that was managed with non-invasive transcutaneous cardiac pacing in the absence of ECMO. The non-invasive transcutaneous pacemaker is a safe, effective and convenient device to revert arrhythmias.

Keywords

III° A-V block, Fulminant Myocarditis, non-invasive transcutaneous cardiac pacing, ECMO

Revised Amendments from Version 1

We have tried to clarify some queries of reviewers and added few points. 1. Regarding types of arrhythmias on fulminant myocarditis: Cardiac arrhythmias are varied in presentation, ranging from Sinus arrest, AV block, Ventricular tachycardia and Ventricular fibrillation during acute phase18. 2. Uses of medicines: High dose of vitamin C is used to reduce the risk of myocardial injury; Coenzyme Q 10 is used for myocardial preservation, fructose diphosphate to improve cardiac metabolism and mannitol to reduce cerebral edema. 3. Regarding prognosis: Acute fulminant myocarditis, if properly and aggressively treated, has excellent long-term survival even if the patient may present with severe hemodynamic compromise 19. Complete heart block on initial ECG may also have an excellent prognosis, although mechanical assistance may be warranted as shown in the study by Lee E Y et. al 1. 4. We have not done any viral marker, autoimmune marker or endomyocardial biopsy.

To read any peer review reports and author responses for this article, follow the "read" links in the Open Peer Review table.

Abbreviations

A-V block- Atrioventricular block; ECG- Electrocardiogram; ECMO- Extracorporeal Membrane Oxygenation; LVEF- Left ventricular ejection fraction

Introduction

Fulminant myocarditis is a life-threatening clinical condition. It is inflammation of myocardium leading to acute heart failure and cardiac conduction abnormalities with rapid deterioration. There are about 10–38% cases of fulminant myocarditis among all cases of acute myocarditis1. Causes of fulminant myocarditis may be of viral, bacterial or non-infectious origin13. Diagnosis of fulminant myocarditis is very difficult because of non-specific symptoms and diagnostic tools. There may be signs of acute heart failure, cardiogenic shock, or life-threatening cardiac arrhythmias. Cardiac arrhythmias are varied in presentation, ranging from Sinus arrest, AV block, Ventricular tachycardia and Ventricular fibrillation during acute phase4. Here we present a case of fulminant myocarditis presenting with different clinical features and IIIº A-V block, which was successfully managed with non-invasive transcutaneous pacing.

Case report

A 3 ½ year old female child having a productive cough and 5–6 episodes of the passage of loose stool for 2 days was taken to local hospital after she had sudden convulsion for about 2 minutes. At the hospital, she again had convulsion for 1–2 minutes and her heart rate dropped to 30 bpm. She was given atropine, dexamethasone, dextrose and per rectal choral hydrate at the local hospital (doses not known) and immediately referred to Renmin Hospital. She had no significant past medical history, drug sensitivity or allergies. On arrival she was conscious but lethargic and dyspnoeic. Both pupils were round, 4mm and reactive to light. Her vitals were T36.4 °C, HR 62 bpm, RR 65/min, BP 90/41mmHg and SPO2 80%. Table 1 shows the results of routine laboratory measurements. Her lips were cyanosed and she had pale and cold extremities. Neck and throat examination was normal. Chest examination showed b/l crackles and irregular heart rate with no murmurs. The abdomen was soft and non-tender. Electrocardiogram (ECG) showed- III° atrio-ventricular (A-V) block; left anterior fascicular block, ST-T changes (Figure 1). She had cardiac arrest three times in the emergency department at 15–20 minutes interval. She was resuscitated with chest compression along with Isoproterenol and adrenaline. Subsequently, her heart rate was maintained in between 70–90 beats/min. Provisional diagnosis was acute fulminant myocarditis with bronchial pneumonia.

Table 1. Laboratory investigations from day of admission to discharge.

Blood Investigations0
DOA
1
DOA
2
DOA
3
DOA
4
DOA
7
DOA
12
DOA
19
DOA
27
DOA
WBC (4–10×10^9/L)19.8620.0217.1618.4215.6112.5110.5210.018.43
Neutrophils (50–75%)68.770.885.480.4747.655.869.357.657.8
Lymphocytes (20–40%)23.922.410.414.445.9372735.935
Monocytes (3–8%)7.36.24.14.15.653.15.65
Eosinophils (0.5–5%)00.5000.61.60.40.61.6
Basophils (0–1%)0.10.10.10.10.30.60.20.30.6
ANC (2–7.5×10^9/L)13.6514.114.6713.677.423.897.834.423.89
ALC (0.8–4×10^9/L)4.742.221.781.887.165.861.683.162.86
Hemoglobin (110–170 g/L)1101079597108110116122129
Platelets count(100–
300×10^9/L)
203200143132403257311403257
ESR (0–15 mm in 1 hr)1
Blood Glucose (3.89–6.11
mmol/L)
11.26.13.84.64.27.25.3
Potassium (K) (3.5–5.4
mmol/L)
4.35.184.463.53.524.134.4
Sodium (Na) (135–148
mmol/L)
131138129133.8134.6141142
Calcium (Ca) (2.05–2.55
mmol/L)
1.581.61.622.272.232.38
Blood Urea (1.8–7.1
mmol/L)
21.3521.4521.796.884.985.294.1
creatinine (44–106 umol/L)158.5167211.663.557.549.650
Uric Acid (129–417 umol/L)977980935274253169
ALT (8–40 U/L)8526658914065525227
AST (5–40 U/L)47243245231930930931
α HBDH ( 72–182 IU/L)389521451061631489192
ALP (40–150 IU/L)151144140127126141
γGGT (7–54 U/L)262828585348
LDH (100–300 IU/L)1014098762155746456223145
Total Protein (60–85 g/L)56.860.463.666.872.872.7
Albumin (35–55 g/L)33.53332394341.1
Globulin ( 20–35 g/L)23.326.931.6343431.6
Creatine Kinase (25–200
IU/L)
117012451679109893935
CKMB (0–25 U/L)24718710448481013
Troponin T (0–0.08 ng/ml)0.3610.0240.018
ASO Titre (0–166 IU/ml)724
CRP (0–10 mg/L)0.90.1
Atrial Blood Gas
PH (7.35 – 7.45)7.347.39ANC: Absolute Neutrophil count

ALC: Absolute Lymphocytes cont
PaO2 (80–100 mmHg)82.188
PaCO2 (35–45 mmHg)2336
HCO3 (22–26 mEq/L)13.324.2
Anion Gap (10–15 mEq/L)3115.2
Stool Routine Normal
Urine routine Normal
Mycoplasma titer Negative
66d306d7-594a-441a-ac7d-8fd70bce8719_Figure1.gif

Figure 1.

(A) Electrocardiogram (ECG) at emergency showing- III°atrio-ventricular block; left anterior fascicular block, ST-T changes; (B) ECG recording during transcutaneous pacing; (C) ECG at the time of discharge, which is normal.

The patient was admitted to hospital after explaining the disease condition and prognosis to parents. She was on continuous oxygen, dopamine, diazepam, Immunoglobulin, ceftriaxone, IV fluids on a maintenance dose and nebulization with Ipratropium bromide (250mcg/ nebulization) along with a high dose of vitamin C (to reduces the risk of myocardial injury), Coenzyme Q 10 (for myocardial protection), fructose diphosphate (to improve cardiac metabolism) and mannitol (to reduce cerebral edema). However, she again had a cardiac arrest. In addition, ECG showed sinus P wave and no QRS with heart rate dropped from 70 to 20bpm. The patient was resuscitated with chest compression, atropine, and adrenaline. Isoproterenol was started at 1.5mcg/kg/min and increased up to 2mcg/kg/min. Subsequently, her heart rate was maintained at 60–70 bpm. Her heart rate again decreased to 30bpm when isoproterenol was discontinued. As there was no extracorporeal membrane oxygenation (ECMO) machine in our hospital and transfer was not possible, the patient was prepped for non-invasive transcutaneous cardiac pacing.

Cardiac pacing was adjusted to 16 mA and rate 90 bpm. The patient’s heart rate was controlled at 80–100 bpm. Her complexion gradually became reddish, cyanosis gradually improved but she had developed eyelid edema. She had passed urine about 130ml twice in 12 hours. Dopamine was increased to 7mcg/kg/min and she was started on furosemide.

At first 24 hours after cardiac pacing, the patient was conscious. She had passed urine 4 times about 700ml. But facial puffiness was still present. Her heart rate was maintained at the rate of 110–130bpm and SPO2 was 96% with oxygen. Chest pacing was reduced to 14 mA, and the frequency was changed to 70 bpm. After 48hours of pacing, the heart rate was improved to 100–110bpm with few ventricular premature beats. Then pacing was reduced to 12 mA, frequency changed to 60bpm. The pacing current and frequency were gradually slowed down and discontinued. Then, sinus rhythm was established with the heart rate of 100–110bpm with ECG monitoring. The heart rate fluctuated at 80–100bpm with frequent ventricular premature beats. Echocardiography showed left ventricular myocardial wall thickening and thickening of endocardium with left ventricular ejection fraction (LVEF 50%), suggestive of endocardial fibroelastosis (EF). Chest radiograph showed increased lung texture and enlarged cardiac shadow (Figure 2). Captopril, hydrochlorothiazide, and spironolactone were started to reduce cardiac remodeling and to protect heart function. Furosemide was continued. Mannitol was stopped after the patient’s MRI scan revealed normal findings.

66d306d7-594a-441a-ac7d-8fd70bce8719_Figure2.gif

Figure 2.

(A) Patient on non-invasive transcutaneous pacing; (B) Echocardiography after 48 hours of admission showing left ventricular myocardial wall thickening and thickening of endocardium; (C) Chest X ray showing increased lung texture and enlarged cardiac shadow.

The patient’s HR was in between 80–100 bpm, with blood pressure was increasing gradually. Dopamine was tapered and stopped at 72 hours, after her BP reached 110/78 mmHg. The chest became gradually clear and her heart sounds were also normal. ECG monitoring also showed improvement with decreased numbers of premature beats and gradual change of S-T segments towards normal.

The patient was discharged on the 28th day after admission after her all routine investigations returned to normal (Table 1). ECG showed sinus rhythm with heart rate 102 bpm. Echocardiography showed normal cardiac chambers, normal wall motion with EF 60%. Her final diagnosis was fulminant myocarditis with III° A-V block and bronchial pneumonia. On discharge, the patient was advised to continue captopril 6.25mg bid, metoprolol succinate 6.25mg bid, prednisone 1mg / kg orally for six months.

At six month follow up the patient’s echocardiography had returned to normal with LVEF 65%, and prednisone was reduced to 0.5mg/kg orally for 15 days and with a tapering dose for the next 15 days. After one year follow-up, she had no complaints and no significant abnormalities noted on echocardiography.

All doses of medications can be seen in Table 2.

Table 2. List of medications, including doses and duration, given to the patient during hospital admission.

Doses of medicine and duration
MedicineDoses Route/duration
Atropine0.25mg IV When reqired
Adrenaline0.2mgIV When reqired
Isoproterenol0.2mcgIV- bolus at ER
0.15mcg/kg/minIV in 50ml of 5% glucose
0.2mcg/kg/minIV in 50ml of 5% glucose
Dopamine3–5mcg/kg/minIV in 50ml of 5% glucose
Diazepam0.5mg/kgIV when reqired
Phenobarbital2mg/kgIV when reqired
Mannitol42 mlIV 6 hourly for 2 days from DOA
42 mlIV 8 hourly for next 2 days
42mlIV 12 hourly for next 2 days then stop
Fructose diphosphate3.4g /ODIV for 10 days
Ceftriaxone100mg/kg/dayIV 12 hourly from DOA for 10 days
Piperacillin tazobactam1.125gm/dayIV 12 hourly from 3 DOA for 10 days
Immunoglobulin5 gmIV daily for 5 days
Methylprednisolone 1.5mg/kg/dayIV for 5 days
prednisone10 mg / ODPO from 6 DOA and on discharge also
Captopril6.25mg / BIDPO from 3 DOA and on discharge also
Spironolactone10mg/ODPO from 5 DOA and on discharge also
Furosemide10mgIV 12hourly from 2nd DOA to 5DOA
Hydrochlorothiazide10mgPO 12 hourly from 5 DOA till discharge
Coenzyme Q105 mgPO 8hourly from 2nd DOA till discharge
Vitamin C3 gm IV 12 hourly from 2nd DOA till discharge

Discussion

In children, sometimes myocarditis is self-limiting. However, if it progresses there is the risk of acute cardiac failure, hemodynamic disturbances, and arrhythmias leading to significant morbidity and mortality. Mortality due to myocarditis for infants is more than 75%, whereas for children it is more than 25%1,59. There is no any specific clinical course and investigations to diagnose fulminant myocarditis. Initially, they present with flu-like symptoms and later develop sudden onset of cardiac symptoms that rapidly deteriorate2. Neonates may present with fever, poor feeding, and listlessness and sometimes with danger signs like apnea, episodic cyanosis, and diaphoresis. Older children present with respiratory or gastrointestinal symptoms. Among them only a few present with chest pain10. Diagnosis is mainly done on the basis of: Clinical presentation, blood profile, including CBC, electrolytes, creatinine kinase, creatine kinase MB isoenzyme, C-reactive protein, Troponin T, Troponin I, antistreptolysin O titer, polymerase chain reaction to detect viral antigens, autoantibodies marker, liver enzymes, ECG, Echocardiography, ultrasonography and even Cardiac MRI3 which are mostly supportive. If echocardiography shows low LVEF in children with fulminant myocarditis, the prognosis is poor11. Mortality in fulminant myocarditis is mainly due to cardiac arrhythmias among which structural changes, parameters of ventricular dynamics and vascular changes are responsible for the increased incidence12. Acute fulminant myocarditis, if properly and aggressively treated, has excellent long-term survival even if the patient may present with severe hemodynamic compromise13. Complete heart block on initial ECG may also have an excellent prognosis, although mechanical assistance may be warranted as shown in the study by Lee E Y et al.1. This can be managed with percutaneous cardiopulmonary support, ECMO, intra-aortic balloon pumping, or the ventricular assisted device14,15. ECMO remains an effective approach in children for the management of acute fulminant myocarditis16. In addition, intravenous immunoglobulin and high dose steroids help to reduce inflammation17. Patients managed with immunoglobulin, steroids or mechanical support for fulminant myocarditis may have higher survival rate compared to those not receiving these therapies14.

In the present case, we tried to manage initially with Isoproterenol but were unsuccessful. So we applied the non-invasive transcutaneous pacemaker to revert the A-V block. Pads or electrodes detachment, patient non-cooperation and skin-burn due to high voltage electric current are its limitations. In contrast, intraventricular cardiac pacing is time-consuming; much more risky and surgical site wound infection is common. Beland et al, Kelly et al in their articles note that non-invasive transcutaneous pacemaker is the safe, effective and suitable equipment for children18,19.

Conclusion

Acute fulminant myocarditis is a grievous condition with high morbidity and mortality. No delay should be had on starting immunoglobulin and steroids if suspected. If there is the arrhythmia, the patient should be immediately started on ECMO, percutaneous cardiopulmonary support or ventricular assisted device. If these are not available, then non-invasive transcutaneous cardiac pacing must be started, which is a safe, convenient and cost-effective device to revert arrhythmias caused by myocarditis.

Consent

We have taken written informed consent from the child`s legal guardian (her father) to use and publish his child`s medical case history and any accompanying images.

Data availability

All data underlying the results are available as part of the article and no additional source data are required.

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 28 Feb 2018
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Devkota K, Wang YH, Liu MY et al. Case Report: III° atrioventricular block due to fulminant myocarditis managed with non-invasive transcutaneous pacing [version 2; peer review: 2 approved]. F1000Research 2018, 7:239 (https://doi.org/10.12688/f1000research.14000.2)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 2
VERSION 2
PUBLISHED 23 Mar 2018
Revised
Views
0
Cite
Reviewer Report 26 Mar 2018
Sabine Pankuweit, Department of Cardiology, Angiology and Intensive Care, Philipps University of Marburg, Marburg, Germany 
Approved
VIEWS 0
Authors have answered the questions raised ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Pankuweit S. Reviewer Report For: Case Report: III° atrioventricular block due to fulminant myocarditis managed with non-invasive transcutaneous pacing [version 2; peer review: 2 approved]. F1000Research 2018, 7:239 (https://doi.org/10.5256/f1000research.15664.r32382)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
3
Cite
Reviewer Report 26 Mar 2018
Mani Prasad Gautam, Department of Medicine, Bharatpur Hospital, Chitwan, Nepal 
Approved
VIEWS 3
The Authors have discussed an interesting case of fulminant myocarditis in a child which have been managed with transcutaneous pacing for the third degree AV block along with other supportive care including intravenous methylprednisolone and immunoglobulin. In overall the article ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Gautam MP. Reviewer Report For: Case Report: III° atrioventricular block due to fulminant myocarditis managed with non-invasive transcutaneous pacing [version 2; peer review: 2 approved]. F1000Research 2018, 7:239 (https://doi.org/10.5256/f1000research.15664.r32381)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Version 1
VERSION 1
PUBLISHED 28 Feb 2018
Views
7
Cite
Reviewer Report 14 Mar 2018
Sabine Pankuweit, Department of Cardiology, Angiology and Intensive Care, Philipps University of Marburg, Marburg, Germany 
Approved
VIEWS 7
The authors described a case of III° atrioventricular block due to fulminant myocarditis that was managed with non-invasive transcutaneous cardiac pacing in the absence of ECMO. In this case the non-invasive transcutaneous pacemaker was a safe, effective and convenient device to ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Pankuweit S. Reviewer Report For: Case Report: III° atrioventricular block due to fulminant myocarditis managed with non-invasive transcutaneous pacing [version 2; peer review: 2 approved]. F1000Research 2018, 7:239 (https://doi.org/10.5256/f1000research.15216.r31964)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
16
Cite
Reviewer Report 05 Mar 2018
Mani Prasad Gautam, Department of Medicine, Bharatpur Hospital, Chitwan, Nepal 
Approved with Reservations
VIEWS 16
The Authors have discussed an interesting  case  of fulminant myocarditis in a child which have been managed with transcutaneous pacing for the third degree AV block along with other supportive care including intravenous methylprednisolone and immunoglobulin. In overall the article ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Gautam MP. Reviewer Report For: Case Report: III° atrioventricular block due to fulminant myocarditis managed with non-invasive transcutaneous pacing [version 2; peer review: 2 approved]. F1000Research 2018, 7:239 (https://doi.org/10.5256/f1000research.15216.r31290)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 28 Feb 2018
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.